Recruiting
Phase 1

Gadobutrol

Sponsor:

National Institute of Neurological Disorders and Stroke (NINDS)

Code:

NCT07796360

Conditions

Healthy Volunteers

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Interventions

Gadobutrol

Study Details

Brief summary:

Background:

Cerebrospinal fluid (CSF) is the liquid that fills the space around the brain and spinal cord. Researchers do not fully understand how CSF flows and drains around the brain. They want to test a tracer (gadobutrol)-a special dye injected into the CSF-to find out if it is safe to use and can help them get clearer pictures of the CSF during magnetic resonance imaging (MRI) scans of the brain.

Objective:

To test gadobutrol in the CSF during MRI scans of healthy people.

Eligibility:

Healthy volunteers aged 18 years and older. They must be screened under NIH protocol 89N0045.

Design:

Participants will check into the clinic for a 3-day stay.

They will have a lumbar puncture: An area on their lower back will be numbed. A thin needle will be inserted into the space around the spinal cord. A sample of CSF will be taken for research. Then a low dose of gadobutrol will be injected into the CSF.

Participants will have 4 or 5 MRI scans of the brain-30 minutes, 4 hours, 8 hours (this one is optional), 24 hours, and 48 hours after receiving the gadobutrol.

For the scan, they will lie on a table that slides into a cylinder. Special padding will be used to hold their head still. The MRI uses magnetic fields to create images of the inside of the body. Blood and urine samples will also be collected at each scan.

Participants will return for an additional MRI 1 week after they leave the clinic. They will have 2 follow-up phone calls 4 and 12 weeks after the start of the study.

Conditions

Healthy Volunteers

Study ID

NCT07796360

Start date

Nov 19, 2026

Status verified date

Nov 12, 2026

Completion date

Mar 15, 2028

Anticipated

Primary completion date

Mar 15, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

  • INCLUSION CRITERIA:

To be eligible to participate in this study, an individual must meet all the following criteria:

  • Healthy volunteer.
  • Age >= 18 years.

To explore age-related effects on tracer dynamics and clearance, 3 cohorts of participants will be recruited: 1) 18-30 years, 2) 30-55 years, and 3) >55 years; with 2 males and 2 females in each age group.

  • Able to give written and oral informed consent.
  • Prior evaluation under NIH protocol 89N0045.
  • Prior intravenous gadolinium administration at any time in the participant s life.

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

  • History of chronic neurological illness, or significant concurrent medical illness.
  • Contraindication to 3- or 7-tesla MRI
  • Hypersensitivity reactions to contrast agents.
  • History of severe allergic reactions.
  • Pregnancy or breastfeeding.
  • Renal dysfunction or other serious comorbidities.
  • Platelet count <100,000/microliter, INR > 1.5 or prolonged PT or aPTT at baseline.
  • Any of the following imaging findings: Mass effect, midline shift, herniation (tonsillar, uncal, subfalcine), or Chiari malformation.
  • History of seizures or seizure disorder.
  • Anti-coagulation therapy.
  • Unwilling to allow coded samples to be processed offsite.
  • Unwilling to have coded samples and/or data saved or used in other studies.

Study Design

Enrollment

15 participants

Anticipated

Allocation

Non randomized

Intervention Model

Single group

Primary purpose

Other

Interventions and Outcome Measures

Arms

experimental: Healthy Volunteer

0.25 mmol IT gadobutrol or 0.5 mmol

Interventions

Gadobutrol

contrast agent

Primary outcome measure

  • Occurrence of intervention-emergent adverse events at the participant level assessed descriptively [ Time Frame: 12-week study period. ]

Central Contacts and Locations

Central contacts

Locations

National Institutes of Health Clinical Center

Recruiting

Bethesda, Maryland, United States, 20892

Contacts

More Information

Sponsor

National Institute of Neurological Disorders and Stroke (NINDS)

Last update posted

Nov 16, 2026

Last verified

Nov 12, 2026

Keywords

  • gadobutrol
  • Intrathecal
  • lymphatics clearance

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-17. This information was provided to ClinicalTrials.gov by National Institute of Neurological Disorders and Stroke (NINDS) on 2026-11-16. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.